Blend Therapeutics
Blend is developing novel cancer therapeutics designed to overcome efficacy barriers for improved targeting of cancer. Blend’s innovative medicines leverage tumor biology to gain therapeutic advantage in unique ways. With their Pentarin platform, they create miniaturized biologic drug conjugate (mBDC) incorporated in polymeric nanoparticles that are designed to reach and penetrate the solid tumor and then selectively kill the targeted cancer cells. With their novel personalized Platinum, they have designed it to take advantage of the biology of certain solid tumor cancer cells by using the cell’s appetite for albumin to increase uptake, leading to enhanced efficacy response.
